VTv Therapeutics

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company concentrated on creating orally administered, small molecule drug candidates. Incorporated in April 2015, the company emerged from the combination of TransTech Pharma and High Point Pharmaceuticals, launching its initial public offering on July 30, 2015. The company is publicly traded on the Nasdaq under the ticker symbol VTVT.

The company's primary business model revolves around the research and development of its proprietary drug candidates, with a strategy centered on strategic partnerships, licensing agreements, and eventual commercialization upon regulatory approval. vTv Therapeutics forges collaborations with academic institutions and other pharmaceutical companies to advance its research, and it outsources manufacturing to contract manufacturing organizations. Revenue generation is anticipated from drug sales post-approval and through licensing deals with partners like Hangzhou Zhongmei Huadong Pharmaceutical and Novo Nordisk A/S.

The lead drug candidate in vTv's pipeline is cadisegliatin (also known as TTP399), an oral, liver-selective glucokinase activator. This drug is being developed as a first-in-class adjunctive therapy to insulin for individuals with Type 1 Diabetes (T1D). Cadisegliatin's mechanism of action is distinct from existing therapies; it works by activating glucokinase in the liver, which helps to trap glucose in liver cells and promote its storage, thereby stabilizing blood glucose levels and reducing the risk of severe hypoglycemia. The FDA has granted Breakthrough Therapy designation to cadisegliatin for the treatment of T1D.

The company is advancing cadisegliatin through late-stage clinical trials. The CATT1 Phase 3 trial is a multicenter, randomized, double-blind, placebo-controlled study evaluating the drug's ability to reduce hypoglycemic events in adults with T1D. Following a temporary clinical hold in July 2024, which the FDA lifted in March 2025, the trial resumed with a modified protocol to shorten its duration to six months, aiming to expedite the availability of topline data expected in the second half of 2026. Beyond T1D, the company's pipeline includes other candidates in earlier stages of development for treating inflammatory diseases and other chronic conditions.

Keywords: biopharmaceutical, clinical-stage, small molecule drugs, oral therapeutics, Type 1 Diabetes, cadisegliatin, TTP399, glucokinase activator, liver-selective, hypoglycemia, adjunctive therapy, metabolic diseases, inflammatory diseases, clinical trials, FDA Breakthrough Therapy, drug development, VTVT, pharmaceutical partnerships, licensing agreements